Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 08h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 02h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Gene Editing Market Size Worth USD 35.84 Billion in 2032 | Emergen Research
30 nov. 2023 03h22 HE
|
Emergen Research
Vancouver, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The global gene editing market size was USD 6.11 Billion in 2021 and is expected to register a revenue CAGR of 17.5% during the forecast period. The...
Yield10 Bioscience Begins 2021 Field Test and Seed Scale Up Program
13 juil. 2021 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has completed planting of its 2021 Field Test and...
Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulated Status of its CRISPR Genome-Edited C3007 Trait in Canola; Plans U.S. Field Tests for 2021
17 août 2020 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from...
Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulatory Status of its CRISPR Genome-Edited C3007 Trait in Camelina, Paving the Way for U.S. Field Tests
27 avr. 2020 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from...
Yield10 Bioscience Submits "Am I Regulated?" Letter to USDA-APHIS BRS for CRISPR Genome-Edited C3007 in Camelina to Pave the Way for U.S. Field Tests
16 janv. 2020 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the...
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present at the 7th Plant Genomics & Gene Editing Congress
05 nov. 2019 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the...
Yield10 Bioscience Signs Research Agreement with J. R. Simplot to Evaluate New Traits to Produce High Yielding, Sustainable Potato Crop
23 oct. 2019 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) today announced that it has signed a research agreement with Boise, Idaho-based J. R. Simplot Company, to...
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Unique Aspects of the Company’s GRAIN Technology Platform to Identify Novel Traits for Crops at the 3rd Precision CRISPR & NBT AgBio Congress
24 juin 2019 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the...